A Functional Polymorphism in the Promoter Region of Interleukin-12B Increases the Risk of Colorectal Cancer.

Publisher: Wiley Country of Publication: United States NLM ID: 101600173 Publication Model: eCollection Cited Medium: Internet ISSN: 2314-6141 (Electronic) NLM ISO Abbreviation: Biomed Res Int Subsets: MEDLINE

Publication: 2024- : [Hoboken, NJ] : Wiley
Original Publication: New York, NY : Hindawi Pub. Co.

Colorectal Neoplasms*/epidemiology ; Colorectal Neoplasms*/genetics; Genetic Predisposition to Disease/*genetics ; Interleukin-12 Subunit p40/*genetics; Aged ; Female ; Humans ; Interleukin-12 Subunit p40/analysis ; Interleukin-12 Subunit p40/metabolism ; Male ; Middle Aged ; Polymorphism, Genetic/genetics ; Promoter Regions, Genetic/genetics ; RNA, Messenger/analysis ; RNA, Messenger/genetics ; RNA, Messenger/metabolism

Competing Interests: The authors report no conflicts of interest in this work.
Objective: To investigate whether the polymorphisms of interleukin-12B ( IL-12B ) were associated with the risk of developing colorectal cancer (CRC). Patients and Methods . Genotypes of rs17860508 and rs3212227 were determined by polymerase chain reaction with a direct sequencing method in 329 CRC patients and 342 matched healthy control subjects. The expression of IL-12B ) were associated with the risk of developing colorectal cancer (CRC).
Results: Compared with TTAGAG/TTAGAG genotype of rs17860508, the GC/GC and TTAGAG/GC genotypes may significantly increase the risk of CRC (OR = 1.81, 95% CI = 1.18-2.78; OR = 1.46, 95% CI = 1.01-2.12, respectively). Furthermore, the mRNA levels of IL-12B ) were associated with the risk of developing colorectal cancer (CRC). P =0.009) and TTAGAG/TTAGAG ( P =0.009) and TTAGAG/TTAGAG (.
Conclusion: These data suggested that the rs17860508 GC/GC genotype might upregulate IL-12B expression at the transcriptional level and thus increase the risk of CRC. IL-12B ) were associated with the risk of developing colorectal cancer (CRC).
(Copyright © 2020 Yabin Liu et al.)

CA Cancer J Clin. 2014 Mar-Apr;64(2):104-17. (PMID: 24639052)
Int J Cancer. 2015 Mar 1;136(5):E359-86. (PMID: 25220842)
Asian Pac J Cancer Prev. 2014;15(18):7869-73. (PMID: 25292079)
Eur J Cancer Prev. 2015 Jul;24(4):296-304. (PMID: 25350634)
Malar J. 2009 Dec 11;8:290. (PMID: 20003322)
Onco Targets Ther. 2013 May 13;6:523-6. (PMID: 23696707)
J Allergy Clin Immunol. 2004 Mar;113(3):475-81. (PMID: 15007350)
Clin Cancer Res. 2009 Jan 1;15(1):400-5. (PMID: 19118071)
J Allergy Clin Immunol. 2005 Oct;116(4):789-95. (PMID: 16210052)
Microbes Infect. 2008 Mar;10(3):224-32. (PMID: 18321748)
Dig Dis. 2015;33(1):52-7. (PMID: 25531497)
Cytokine. 2005 May 21;30(4):188-94. (PMID: 15863393)
Cancer Invest. 2009 Nov;27(9):924-31. (PMID: 19832040)
Pathol Oncol Res. 2012 Oct;18(4):997-1002. (PMID: 22614250)
Dis Esophagus. 2015 Apr;28(3):291-8. (PMID: 24529168)
MAbs. 2010 Sep-Oct;2(5):539-49. (PMID: 20724822)
Nucleic Acids Res. 1988 Feb 11;16(3):1215. (PMID: 3344216)
Clin Cancer Res. 2007 Aug 15;13(16):4677-85. (PMID: 17699845)
Diabetes. 2002 Jul;51(7):2334-6. (PMID: 12086971)
Am J Gastroenterol. 2003 Jul;98(7):1588-93. (PMID: 12873583)
World J Gastroenterol. 2008 Jan 28;14(4):532-40. (PMID: 18203284)
Carcinogenesis. 2007 Jul;28(7):1437-41. (PMID: 17361014)
Cancer Lett. 2012 Sep 1;322(1):92-7. (PMID: 22366581)
Surg Today. 2004;34(12):1014-9. (PMID: 15580384)
Scand J Immunol. 2016 Jul;84(1):49-60. (PMID: 27059274)
Cancer Immunol Immunother. 2015 Feb;64(2):181-90. (PMID: 25324197)
Clin Exp Allergy. 2009 Feb;39(2):228-35. (PMID: 19134014)
Int J Cancer. 2011 Apr 1;128(7):1692-6. (PMID: 20521253)
Scand J Immunol. 2012 Sep;76(3):329-35. (PMID: 22702905)

0 (IL12B protein, human)
0 (Interleukin-12 Subunit p40)
0 (RNA, Messenger)

Date Created: 20200310 Date Completed: 20201216 Latest Revision: 20220413

20250114

PMC7054766

10.1155/2020/2091781

32149085